Cytokine release syndrome in a patient with non-small cell lung cancer on ipilimumab and nivolumab maintenance therapy after vaccination with the mRNA-1273 vaccine: a case report.

ABSTRACT:

Background

Cytokine release syndrome (CRS) is caused by the release of inflammatory cytokines that appear during or immediately after administration of a therapeutic antibody and can cause a variety of symptoms. COVID-19 vaccination is effective in cancer patients and prevents breakthrough infections. The safety of vaccines during immune checkpoint inhibitor (ICI) therapy has been reported; however, multiple vaccinations have been developed in recent years, and it is unclear whether repeated vaccinations play a role in the development of CRS in patients receiving ICI.

Case description

A 55-year-old man with stage IV non-small cell lung cancer received ipilimumab and nivolumab maintenance therapy; adverse reactions during the first and second COVID-19 vaccinations (BNT162b2)

SUBMITTER: Sumi T 

PROVIDER: S-EPMC9554683 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature